Merops Switch to
Inhibitors

Peptidase

Family Clan SEARCHES BLAST
MEROPS SUBMISSIONS

Other
information

Literature for peptidase S01.214: coagulation factor IXa

Summary Gene structure Alignment Tree Sequences Sequence features Distribution Structure Literature Substrates Pharma

(Topics flags: A Assay, S Structure, T Target, K Knockout, E Expression, V Review, M Mutation, I Inhibitor, U Therapeutic. To select only the references relevant to a single topic, click the link above. See explanation.)

    2025
  1. Bozhko,A.A. and Panteleev,M.A.
    A mathematical model for activated platelet-dependent activation of coagulation factor X by factor IXa
    Comput Biol Med192, 110263-110263. PubMed  Europe PubMed DOI
    2. 2024
  2. Bos,M.H.A., van Diest,R.E. and Monroe,D.M.
    Blood coagulation factor IX: structural insights impacting hemophilia B therapy
    Blood144, 2198-2210. PubMed  Europe PubMed DOI  V
  3. Coyle,C.W., Knight,K.A., Brown,H.C., George,S.N., Denning,G., Branella,G.M., Childers,K.C., Spiegel,P.C., Spencer,H.T. and Doering,C.B.
    Humanization and functional characterization of enhanced coagulation factor IX variants identified through ancestral sequence reconstruction
    J Thromb Haemost22, 633-644. PubMed  Europe PubMed DOI
  4. Fang,L., Jin,J., Zhang,Z., Yu,S., Tian,C., Luo,F., Long,M., Zuo,H. and Lou,S.
    Antidote-controlled DNA aptamer modulates human factor IXa activity
    Bioorg Chem148, 107463-107463. PubMed  Europe PubMed DOI
  5. Kolyadko,V.N., Layzer,J.M., Perry,K., Sullenger,B.A. and Krishnaswamy,S.
    An RNA aptamer exploits exosite-dependent allostery to achieve specific inhibition of coagulation factor IXa
    Proc Natl Acad Sci U S A121, e2401136121-e2401136121. PubMed  Europe PubMed DOI
  6. Ma,Y., Li,Y., Sun,J., Liang,Q., Wu,R., Ding,Q. and Dai,J.
    Complete F9 Gene Deletion, Duplication, and Triplication Rearrangements: Implications for Factor IX Expression and Clinical Phenotypes
    Thromb Haemost124, 374-385. PubMed  Europe PubMed DOI
  7. Misenheimer,T.M., Lasarev,M.R., Kumfer,K.T., Sheehan,J.P. and Schwartz,B.S.
    A novel factor IXa-specific enzyme-linked immunosorbent assay detects factor IXa in human plasma
    Res Pract Thromb Haemost8, 102338-102338. PubMed  Europe PubMed DOI
  8. Oda,A., Takeyama,M., Kitazawa,T. and Nogami,K.
    The emicizumab-bridged ternary complex with activated factor IX and factor X evaluated by fluorescence resonance energy transfer
    Thromb Res237, 108-111. PubMed  Europe PubMed DOI
  9. Ortel,T.L.
    Introduction to a review series on von Willebrand factor, factor VIII, and factor IX
    Blood144, 2157-2158. PubMed  Europe PubMed DOI
  10. Park,B.H., Yun,H. and Jeong,H.J.
    Soluble expression of recombinant coagulation factor IX protein using Escherichia coli
    Biochem Biophys Rep38, 101714-101714. PubMed  Europe PubMed DOI
  11. Soloveva,P.A., Podoplelova,N.A. and Panteleev,M.A.
    Binding of coagulation factor IXa to procoagulant platelets revisited: Low affinity and interactions with other factors
    Biochem Biophys Res Commun720, 150099-150099. PubMed  Europe PubMed DOI
  12. Wei,X., Zhang,H., Chen,W., Zhang,J. and Dai,J.
    A study of recurrent life-threatening thrombosis accompanied with the duplication of the factor IX gene
    Thromb J22, 1-1. PubMed  Europe PubMed DOI
    13. 2023
  13. Abraham,S. and Duncan,E.M.
    A Review of Factor VIII and Factor IX Assay Methods for Monitoring Extended Half-Life Products in Hemophilia A and B
    Methods Mol Biol2663, 569-588. PubMed  Europe PubMed DOI  V
  14. Desage,S., Leuci,A., Enjolras,N., Holle,L.A., Singh,S., Delavenne,X., Wolberg,A.S., Biswas,A. and Dargaud,Y.
    Characterization of a recombinant factor IX molecule fused to coagulation factor XIII-B subunit
    Haemophilia29, 1483-1489. PubMed  Europe PubMed DOI
  15. Ge,R., Wang,C., Liu,J., Jiang,H., Jiang,X. and Liu,Z.
    A Novel Tumor-Promoting Role for Nuclear Factor IX in Glioblastoma Is Mediated through Transcriptional Activation of GINS1
    Mol Cancer Res21, 189-198. PubMed  Europe PubMed DOI  K
  16. Turkut Tan,T., Pariltay,E., Avci Durmusaliogu,E., Isik,E., Cogulu,O., Kavakli,K. and Atik,T.
    A unique case of thrombophilia: the role of F9 gene duplication and increased factor IX activity in cerebral venous thrombosis
    J Thromb Haemost21, 2913-2916. PubMed  Europe PubMed DOI
  17. Wang,R., Jiang,S., Wang,X., Wei,D., Xu,Q. and Wu,W.
    Structural and functional exploration of three newly identified coagulation factor IX mutations in Chinese hemophilia B patients
    Int J Hematol118, 201-209. PubMed  Europe PubMed DOI
  18. Yoon,H.J., Kundu,S. and Wu,S.
    Molecular Dynamics Simulation Study of the Selective Inhibition of Coagulation Factor IXa over Factor Xa
    Molecules28, PubMed  Europe PubMed DOI
    19. 2022
  19. Afosah,D.K., Ofori,E., Mottamal,M. and Al-Horani,R.A.
    Factor IX(a) inhibitors: an updated patent review (2003-present)
    Expert Opin Ther Pat1-20. PubMed  Europe PubMed DOI
  20. Beauglehole,A.C., Roche Recinos,D., Pegg,C.L., Lee,Y.Y., Turnbull,V., Herrmann,S., Marcellin,E., Howard,C.B. and Schulz,B.L.
    Recent advances in the production of recombinant factor IX: bioprocessing and cell engineering
    Crit Rev Biotechnol1-19. PubMed  Europe PubMed DOI  V
  21. Majumder,R.
    Phosphatidylserine Regulation of Coagulation Proteins Factor IXa and Factor VIIIa
    J Membr Biol255, 733-737. PubMed  Europe PubMed DOI  V
  22. Sato,R., Watanabe,K., Kamata,R. and Takeda,K.
    Development of a sandwich enzyme-linked immunosorbent assay (ELISA) to quantify gamma-glutamyl-carboxylated clotting factor IX and assess redox susceptibility of anticoagulant chemicals
    J Vet Med Sci84, 804-808. PubMed  Europe PubMed DOI
  23. Vatandoost,J. and Bos,M.H.A.
    Effect of prepropeptide replacement on gamma-carboxylation and activity of recombinant coagulation factor IX
    Biotechnol Lett44, 975-984. PubMed  Europe PubMed DOI
    24. 2021
  24. Freato,N., van Alphen,F.P.J., Boon-Spijker,M., van den Biggelaar,M., Meijer,A.B., Mertens,K. and Ebberink,E.H.T.M.
    Probing activation-driven changes in coagulation factor IX by mass spectrometry
    J Thromb Haemost PubMed  Europe PubMed DOI
  25. Kearney,K.J., Butler,J., Posada,O.M., Wilson,C., Heal,S., Ali,M., Hardy,L., Ahnstrom,J., Gailani,D., Foster,R., Hethershaw,E., Longstaff,C. and Philippou,H.
    Kallikrein directly interacts with and activates Factor IX, resulting in thrombin generation and fibrin formation independent of Factor XI
    Proc Natl Acad Sci U S A118, PubMed  Europe PubMed DOI
  26. Knight,K.A., Coyle,C.W., Radford,C.E., Parker,E.T., Fedanov,A., Shields,J.M., Szlam,F., Purchel,A., Chen,M., Denning,G., Sniecinski,R.M., Lollar,P., Spencer,H.T., Gaucher,E.A. and Doering,C.B.
    Identification of coagulation factor IX variants with enhanced activity through ancestral sequence reconstruction
    Blood Adv5, 3333-3343. PubMed  Europe PubMed DOI
  27. Kundu,S. and Wu,S.
    A Structure Based Study of Selective Inhibition of Factor IXa over Factor Xa
    Molecules26, PubMed  Europe PubMed DOI
  28. Larson,E.A., Larson,H.J., Taylor,J.A. and Klein,R.F.
    Deletion of Coagulation Factor IX Compromises Bone Mass and Strength: Murine Model of Hemophilia B (Christmas Disease)
    Calcif Tissue Int PubMed  Europe PubMed DOI
  29. Lombardi,S., Aaen,K.H., Nilsen,J., Ferrarese,M., Gjolberg,T.T., Bernardi,F., Pinotti,M., Andersen,J.T. and Branchini,A.
    Fusion of engineered albumin with factor IX Padua extends half-life and improves coagulant activity
    Br J Haematol PubMed  Europe PubMed DOI
  30. Miller,C.H.
    The Clinical Genetics of Hemophilia B (Factor IX Deficiency)
    Appl Clin Genet14, 445-454. PubMed  Europe PubMed DOI
  31. Robinson,M.M., George,L.A., Carr,M.E., Samelson-Jones,B.J., Arruda,V.R., Murphy,J.E., Rybin,D., Rupon,J., High,K.A. and Tiefenbacher,S.
    Factor IX Assay Discrepancies in the Setting of Liver Gene Therapy Using a Hyperfunctional Variant Factor IX-Padua
    J Thromb Haemost PubMed  Europe PubMed DOI
  32. Samelson-Jones,B.J., Finn,J.D., Raffini,L.J., Merricks,E.P., Camire,R.M., Nichols,T.C. and Arruda,V.R.
    Evolutionary insights into coagulation factor IX Padua and other high-specific-activity variants
    Blood Adv5, 1324-1332. PubMed  Europe PubMed DOI
  33. Wu,W., Xiao,L., Wu,X., Xie,X., Li,P., Chen,C., Zheng,Z., Ai,J., Valencia,A., Dong,B., Ding,Q., Dong,B. and Wang,X.
    Factor IX alteration p.Arg338Gln (FIX Shanghai) potentiates FIX clotting activity and causes thrombosis
    Haematologica26, 568-585. PubMed  Europe PubMed DOI  M
  34. Yin,R. and Liu,C.
    Human coagulation factor IX: a systematic review of its characteristics
    Blood Coagul Fibrinolysis PubMed  Europe PubMed DOI
    35. 2020
  35. Nichols,T.C., Levy,H., Merricks,E.P., Raymer,R.A. and Lee,M.L.
    Preclinical evaluation of a next-generation, subcutaneously administered, coagulation factor IX variant, dalcinonacog alfa
    PLoS ONE15, e0240896-e0240896. PubMed  Europe PubMed DOI
  36. Noubouossie,D.F., Henderson,M.W., Mooberry,M., Ilich,A., Ellsworth,P., Piegore,M., Skinner,S.C., Pawlinski,R., Welsby,I., Renne,T., Hoffman,M., Monroe,D.M. and Key,N.S.
    Red blood cell microvesicles activate the contact system leading to factor IX activation via two independent pathways
    Blood135, 755-765. PubMed  Europe PubMed DOI
  37. Pegg,C.L., Zacchi,L.F., Recinos,D.R., Howard,C.B. and Schulz,B.L.
    Identification of novel glycosylation events on human serum-derived factor IX
    Glycoconj J PubMed  Europe PubMed DOI
  38. Shima,M.
    Bispecific Antibodies and Advances in Non-Gene Therapy Options in Hemophilia
    Res Pract Thromb Haemost4, 446-454. PubMed  Europe PubMed DOI
  39. Sousa Bomfim,A., Correa de Freitas,M.C., Picanco Castro,V., Abreu Soares Neto,M., Padua,R., Covas,D.T. and Sousa Russo,E.M.
    Generation of hyperfunctional recombinant human factor IX variants expressed in human cell line SK-Hep-1
    Biotechnol Lett PubMed  Europe PubMed DOI
  40. Takeyama,M., Nogami,K., Matsumoto,T., Noguchi-Sasaki,M., Kitazawa,T. and Shima,M.
    An anti-factor IXa/factor X bispecific antibody, emicizumab, improves ex vivo coagulant potentials in plasma from patients with acquired hemophilia A
    J Thromb Haemost18, 825-833. PubMed  Europe PubMed DOI
    41. 2019
  41. Alexaki,A., Hettiarachchi,G.K., Athey,J.C., Katneni,U.K., Simhadri,V., Hamasaki-Katagiri,N., Nanavaty,P., Lin,B., Takeda,K., Freedberg,D., Monroe,D., McGill,J.R., Peters,R., Kames,J.M., Holcomb,D.D., Hunt,R.C., Sauna,Z.E., Gelinas,A., Janjic,N., DiCuccio,M., Bar,H., Komar,A.A. and Kimchi-Sarfaty,C.
    Effects of codon optimization on coagulation factor IX translation and structure: Implications for protein and gene therapies
    Sci Rep9, 15449-15449. PubMed  Europe PubMed DOI  E
  42. Bahrami,S., Ghaffari,M. and Zomorodipour,A.
    Production of recombinant human factor IX by propeptide modification in Drosophila S2 cell line
    Biotechnol Lett41, 347-355. PubMed  Europe PubMed DOI  E
  43. Meireles,M.R., Bragatte,M.A.S., Bandinelli,E., Salzano,F.M. and Vieira,G.F.
    A new in silico approach to investigate molecular aspects of factor IX missense causative mutations and their impact on the hemophilia B severity
    Hum Mutat40, 706-715. PubMed  Europe PubMed DOI  M
  44. Saini,S., Croteau,S.E., Horling,F.M. and Dunn,A.L.
    Factor IX inhibitors: clinical and laboratory profiles of two patients with severe haemophilia B
    Haemophilia25, e126-e126. PubMed  Europe PubMed DOI  M
  45. Spronck,E.A., Liu,Y.P., Lubelski,J., Ehlert,E., Gielen,S., Montenegro-Miranda,P., de Haan,M., Nijmeijer,B., Ferreira,V., Petry,H. and van Deventer,S.J.
    Enhanced factor IX activity following administration of AAV5-R338L "Padua" factor IX versus AAV5 WT human factor IX in NHPs
    Mol Ther Methods Clin Dev15, 221-231. PubMed  Europe PubMed DOI  M
  46. Vadivel,K., Schreuder,H.A., Liesum,A., Schmidt,A.E., Goldsmith,G. and Bajaj,S.P.
    Sodium-site in serine protease domain of human coagulation factor IXa: evidence from the crystal structure and molecular dynamics simulations study
    J Thromb Haemost17, 574-584. PubMed  Europe PubMed DOI  S
  47. Vatandoost,J. and Bos,M.H.A.
    Improved activity and expression of recombinant human factor IX by propeptide engineering
    Daru27, 653-660. PubMed  Europe PubMed DOI  E  U
  48. Wang,X., Gao,L., Shen,N., Liu,A., Lu,Y. and Hu,Q.
    Mutation of factor IX Cys178 is intolerant and may cause severe hemophilia B
    Thromb Res183, 108-110. PubMed  Europe PubMed DOI  M
  49. Xie,C., Wang,Z., Su,Y., Wang,J. and Shen,W.C.
    Discovery of an orally effective factor IX-transferrin fusion protein for hemophilia B
    Int J Mol Sci21, PubMed  Europe PubMed DOI
    50. 2018
  50. Collins,P.W., Quon,D.V.K., Makris,M., Chowdary,P., Kempton,C.L., Apte,S.J., Ramanan,M.V., Hay,C.R.M., Drobic,B., Hua,Y., Babinchak,T.J. and Gomperts,E.D.
    Pharmacokinetics, safety and efficacy of a recombinant factor IX product, trenonacog alfa in previously treated haemophilia B patients
    Haemophilia24, 104-112. PubMed  Europe PubMed DOI  U
  51. Kershaw,G.W., Dissanayake,K., Chen,V.M. and Khoo,T.L.
    Evaluation of chromogenic factor IX assays by automated protocols
    Haemophilia24, 492-501. PubMed  Europe PubMed DOI  A
  52. Kovnir,S.V., Orlova,N.A., Shakhparonov,M.I., Skryabin,K.G., Gabibov,A.G. and Vorobiev,I.I.
    A highly productive CHO cell line secreting human blood clotting factor IX
    Acta Naturae10, 51-65. PubMed  Europe PubMed  E
  53. Le Quellec,S., Enjolras,N., Perot,E., Girard,J., Negrier,C. and Dargaud,Y.
    Fusion of factor IX to factor XIII-B sub-unit improves the pharmacokinetic profile of factor IX
    Thromb Haemost118, 2053-2063. PubMed  Europe PubMed DOI  E  U
  54. Miesbach,W., Meijer,K., Coppens,M., Kampmann,P., Klamroth,R., Schutgens,R., Tangelder,M., Castaman,G., Schwable,J., Bonig,H., Seifried,E., Cattaneo,F., Meyer,C. and Leebeek,F.W.G.
    Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B
    Blood131, 1022-1031. PubMed  Europe PubMed DOI  U
  55. Perez Botero,J., Coon,L.M., Majerus,J.A., Chen,D. and Pruthi,R.K.
    Factor IX gene (F9) genotyping trends and spectrum of mutations identified: a reference laboratory experience
    Semin Thromb Hemost44, 287-292. PubMed  Europe PubMed DOI  M
  56. Vandendriessche,T. and Chuah,M.K.
    Hyperactive factor IX Padua: a game-changer for hemophilia gene therapy
    Mol Ther26, 14-16. PubMed  Europe PubMed DOI  M
  57. Vatandoost,J. and Zarei Sani,O.
    Effect of propeptide amino acid substitution in gamma-carboxylation, activity and expression of recombinant human coagulation factor IX
    Biotechnol Prog34, 515-520. PubMed  Europe PubMed DOI  E
  58. Weber,A., Engelmaier,A., Voelkel,D., Pachlinger,R., Scheiflinger,F., Monahan,P.E. and Rottensteiner,H.
    Development of methods for the selective measurement of the single amino acid exchange variant coagulation factor IX Padua
    Mol Ther Methods Clin Dev10, 29-37. PubMed  Europe PubMed DOI  A  M
    59. 2017
  59. Branchini,A., Ferrarese,M., Campioni,M., Castaman,G., Mari,R., Bernardi,F. and Pinotti,M.
    Specific factor IX mRNA and protein features favor drug-induced readthrough over recurrent nonsense mutations
    Blood129, 2303-2307. PubMed  Europe PubMed DOI  U
  60. George,L.A., Sullivan,S.K., Giermasz,A., Rasko,J.E.J., Samelson-Jones,B.J., Ducore,J., Cuker,A., Sullivan,L.M., Majumdar,S., Teitel,J., McGuinn,C.E., Ragni,M.V., Luk,A.Y., Hui,D., Wright,J.F., Chen,Y., Liu,Y., Wachtel,K., Winters,A., Tiefenbacher,S., Arruda,V.R., van der Loo,J.C.M., Zelenaia,O., Takefman,D., Carr,M.E., Couto,L.B., Anguela,X.M. and High,K.A.
    Hemophilia B gene therapy with a high-specific-activity factor IX variant
    N Engl J Med377, 2215-2227. PubMed  Europe PubMed DOI
  61. Lenting,P.J., Denis,C.V. and Christophe,O.D.
    Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?
    Blood130, 2463-2468. PubMed  Europe PubMed DOI
  62. Lillicrap,D.
    FIX It in One Go: enhanced factor IX gene therapy for hemophilia B
    Cell171, 1478-1480. PubMed  Europe PubMed DOI  U
  63. Ramaswamy,S., Tonnu,N., Tachikawa,K., Limphong,P., Vega,J.B., Karmali,P.P., Chivukula,P. and Verma,I.M.
    Systemic delivery of factor IX messenger RNA for protein replacement therapy
    Proc Natl Acad Sci U S A114, E1941-E1950. PubMed  Europe PubMed DOI  U
  64. Sakurada,I., Endo,T., Hikita,K., Hirabayashi,T., Hosaka,Y., Kato,Y., Maeda,Y., Matsumoto,S., Mizuno,T., Nagasue,H., Nishimura,T., Shimada,S., Shinozaki,M., Taguchi,K., Takeuchi,K., Yokoyama,T., Hruza,A., Reichert,P., Zhang,T., Wood,H.B., Nakao,K. and Furusako,S.
    Discovery of novel aminobenzisoxazole derivatives as orally available factor IXa inhibitors
    Bioorg Med Chem Lett27, 2622-2628. PubMed  Europe PubMed DOI  I
  65. Simhadri,V.L., Hamasaki-Katagiri,N., Lin,B.C., Hunt,R., Jha,S., Tseng,S.C., Wu,A., Bentley,A.A., Zichel,R., Lu,Q., Zhu,L., Freedberg,D.I., Monroe,D.M., Sauna,Z.E., Peters,R., Komar,A.A. and Kimchi-Sarfaty,C.
    Single synonymous mutation in factor IX alters protein properties and underlies haemophilia B
    J Med Genet54, 338-345. PubMed  Europe PubMed DOI  M
    66. 2016
  66. Ankrom,W., Wood,H.B., Xu,J., Geissler,W., Bateman,T., Chatterjee,M.S., Feng,K.I., Metzger,J.M., Strapps,W.R., Tadin-Strapps,M., Seiffert,D. and Andre,P.
    Preclinical and translational evaluation of coagulation factor IXa as a novel therapeutic target
    Pharmacol Res Perspect4, e00207-e00207. PubMed  Europe PubMed DOI  T
  67. Choudhury,S., Plautz,W.E., Zacarias,C. and Majumder,R.
    Mini-review on "A novel one-step purification of mouse factor IX"
    J Rare Dis Res Treat1, 8-10. PubMed  Europe PubMed  V  U
  68. do Amaral,R.L., de Sousa Bomfim,A., de Abreu-Neto,M.S., Picanco-Castro,V., de Sousa Russo,E.M., Covas,D.T. and Swiech,K.
    Approaches for recombinant human factor IX production in serum-free suspension cultures
    Biotechnol Lett38, 385-394. PubMed  Europe PubMed DOI  E
  69. Kristensen,L.H., Olsen,O.H., Blouse,G.E. and Brandstetter,H.
    Releasing the brakes in coagulation factor IXa by co-operative maturation of the substrate-binding site
    Biochem J473, 2395-2411. PubMed  Europe PubMed DOI
  70. Monroe,D.M., Jenny,R.J., Van Cott,K.E., Buhay,S. and Saward,L.L.
    Characterization of IXINITY(R) (trenonacog alfa), a recombinant factor IX with primary sequence corresponding to the threonine-148 polymorph
    Adv Hematol2016, 7678901-7678901. PubMed  Europe PubMed DOI
  71. Negrier,C., Abdul Karim,F., Lepatan,L.M., Lienhart,A., Lopez-Fernandez,M.F., Mahlangu,J., Pabinger,I., Li,Y., Wolko,D., Voigt,C., Jacobs,I. and Santagostino,E.
    Efficacy and safety of long-acting recombinant fusion protein linking factor IX with albumin in haemophilia B patients undergoing surgery
    Haemophilia22, e259-e266. PubMed  Europe PubMed DOI  U
  72. Pilli,V.S., Plautz,W.E., Monroe DM 3rd and Majumder,R.
    A novel one-step purification of mouse factor IX
    Thromb Res139, 125-126. PubMed  Europe PubMed DOI
  73. Santagostino,E.
    Transforming the treatment for hemophilia B patients: update on the clinical development of recombinant fusion protein linking recombinant coagulation factor IX with recombinant albumin (rIX-FP)
    Thromb Res141 Suppl 3, S5-S8. PubMed  Europe PubMed DOI  U
  74. Toby,G.G., Liu,T., Buyue,Y., Zhang,X., Bitonti,A.J., Pierce,G.F., Sommer,J.M., Jiang,H. and Peters,R.T.
    Recombinant factor IX Fc fusion protein maintains full procoagulant properties and exhibits prolonged efficacy in hemophilia B mice
    PLoS ONE11, e0148255-e0148255. PubMed  Europe PubMed DOI  E
  75. Vatandoost,J. and Bos,M.H.
    Efficient expression of functional human coagulation factor IX in stably-transfected Drosophila melanogaster S2 cells; comparison with the mammalian CHO system
    Biotechnol Lett38, 1691-1698. PubMed  Europe PubMed DOI  E
    76. 2015
  76. Dumont,J.A., Loveday,K.S., Light,D.R., Pierce,G.F. and Jiang,H.
    Evaluation of the toxicology, pharmacokinetics, and local tolerance of recombinant factor IX Fc fusion protein in animals
    Thromb Res136, 371-378. PubMed  Europe PubMed DOI  U
  77. Enjolras,N., Perot,E., Le Quellec,S., Indalecio,A., Girard,J., Negrier,C. and Dargaud,Y.
    In vivo efficacy of human recombinant factor IX produced by the human hepatoma cell line HuH-7
    Haemophilia21, e317-e321. PubMed  Europe PubMed DOI  E  U
  78. Khorshidi,S., Zomorodipour,A., Behmanesh,M., Vatandoost,J. and Bos,M.H.
    Functional expression of the human coagulation factor IX using heterologous signal peptide and propeptide sequences in mammalian cell line
    Biotechnol Lett37, 1773-1781. PubMed  Europe PubMed DOI  E
  79. Lu,Q., Yang,L., Manithody,C., Wang,X. and Rezaie,A.R.
    Expression and characterization of Gly-317 variants of factor IX causing variable bleeding in hemophilia B patients
    Biochemistry54, 3814-3821. PubMed  Europe PubMed DOI  M
  80. Meng,D., Andre,P., Bateman,T.J., Berger,R., Chen,Y.H., Desai,K., Dewnani,S., Ellsworth,K., Feng,D., Geissler,W.M., Guo,L., Hruza,A., Jian,T., Li,H., Metzger,J., Parker,D.L., Reichert,P., Sherer,E.C., Smith,C.J., Sonatore,L.M., Tschirret-Guth,R., Wu,J., Xu,J., Zhang,T., Campeau,L.C., Orr,R., Poirier,M., McCabe-Dunn,J., Araki,K., Nishimura,T., Sakurada,I., Hirabayashi,T. and Wood,H.B.
    Development of a novel tricyclic class of potent and selective FIXa inhibitors
    Bioorg Med Chem Lett25, 5437-5443. PubMed  Europe PubMed DOI  S  I
  81. Monahan,P.E., Sun,J., Gui,T., Hu,G., Hannah,W.B., Wichlan,D.G., Wu,Z., Grieger,J.C., Li,C., Suwanmanee,T., Stafford,D.W., Booth,C.J., Samulski,J.J., Kafri,T., McPhee,S.W. and Samulski,R.J.
    Employing a gain-of-function factor IX variant R338L to advance the efficacy and safety of hemophilia B human gene therapy: preclinical evaluation supporting an ongoing adeno-associated virus clinical trial
    Hum Gene Ther26, 69-81. PubMed  Europe PubMed DOI  U
  82. Nakamura,Y., Murata,M., Takagi,Y., Kozuka,T., Nakata,Y., Hasebe,R., Takagi,A., Kitazawa,J., Shima,M. and Kojima,T.
    SVA retrotransposition in exon 6 of the coagulation factor IX gene causing severe hemophilia B
    Int J Hematol102, 134-139. PubMed  Europe PubMed DOI  M
  83. Parker DL Jr, Walsh,S., Li,B., Kim,E., Sharipour,A., Smith,C., Chen,Y.H., Berger,R., Harper,B., Zhang,T., Park,M., Shu,M., Wu,J., Xu,J., Dewnani,S., Sherer,E.C., Hruza,A., Reichert,P., Geissler,W., Sonatore,L., Ellsworth,K., Balkovec,J., Greenlee,W. and Wood,H.B.
    Rapid development of two factor IXa inhibitors from hit to lead
    Bioorg Med Chem Lett25, 2321-2325. PubMed  Europe PubMed DOI  I
  84. Perot,E., Enjolras,N., Le Quellec,S., Indalecio,A., Girard,J., Negrier,C. and Dargaud,Y.
    Expression and characterization of a novel human recombinant factor IX molecule with enhanced in vitro and in vivo clotting activity
    Thromb Res135, 1017-1024. PubMed  Europe PubMed DOI  E  U
  85. Powell,J., Shapiro,A., Ragni,M., Negrier,C., Windyga,J., Ozelo,M., Pasi,J., Baker,R., Potts,J., Li,S., Mei,B., Pierce,G.F. and Robinson,B.
    Switching to recombinant factor IX Fc fusion protein prophylaxis results in fewer infusions, decreased factor IX consumption and lower bleeding rates
    Br J Haematol168, 113-123. PubMed  Europe PubMed DOI  U
  86. Turecek,P.L., Abbuhl,B., Tangada,S.D., Chapman,M., Gritsch,H., Rottensteiner,H., Schrenk,G., Mitterer,A., Dietrich,B., Hollriegl,W., Schiviz,A., Horling,F., Reipert,B.M., Muchitsch,E.M., Pavlova,B.G. and Scheiflinger,F.
    Nonacog gamma, a novel recombinant factor IX with low factor IXa content for treatment and prophylaxis of bleeding episodes
    Expert Rev Clin Pharmacol8, 163-177. PubMed  Europe PubMed DOI
  87. Urasinski,T., Stasyshyn,O., Andreeva,T., Rusen,L., Perina,F.G., Oh,M.S., Chapman,M., Pavlova,B.G., Valenta-Singer,B. and Abbuehl,B.E.
    Recombinant factor IX (BAX326) in previously treated paediatric patients with haemophilia B: a prospective clinical trial
    Haemophilia21, 196-203. PubMed  Europe PubMed DOI  U
  88. Zhang,R., Wang,Q., Zhang,L. and Chen,S.
    Optimized human factor IX expression cassettes for hepatic-directed gene therapy of hemophilia B
    Front Med9, 90-99. PubMed  Europe PubMed DOI  E  U
  89. Zhang,T., Andre,P., Bateman,T.J., Chen,Y.H., Desai,K., Ellsworth,K., Geissler,W.M., Guo,L., Hruza,A., Jian,T., Meng,D., Parker DL Jr, Qian,X., Reichert,P., Sherer,E.C., Shu,M., Smith,C.J., Sonatore,L.M., Tschirret-Guth,R., Nolting,A.F., Orr,R., Campeau,L.C., Araki,K., Nishimura,T., Sakurada,I. and Wood,H.B.
    Development of a novel class of potent and selective FIXa inhibitors
    Bioorg Med Chem Lett25, 4945-4949. PubMed  Europe PubMed DOI  I
    90. 2014
  90. Cao,D.H., Liu,X.L., Mu,K., Ma,X.W., Sun,J.L., Bai,X.Z., Lin,C.K. and Jin,C.L.
    Identification and genetic analysis of a factor IX gene intron 3 mutation in a hemophilia B pedigree in China
    Turk J Haematol31, 226-230. PubMed  Europe PubMed DOI  M
  91. Ducore,J.M., Miguelino,M.G. and Powell,J.S.
    Alprolix (recombinant factor IX Fc fusion protein): extended half-life product for the prophylaxis and treatment of hemophilia B
    Expert Rev Hematol7, 559-571. PubMed  Europe PubMed DOI  U
  92. Gailani,D., Geng,Y., Verhamme,I., Sun,M.F., Bajaj,S.P., Messer,A. and Emsley,J.
    The mechanism underlying activation of factor IX by factor XIa
    Thromb Res133 Suppl 1, S48-S51. PubMed  Europe PubMed DOI
  93. Liu,J., Jonebring,A., Hagstrom,J., Nystrom,A.C. and Lovgren,A.
    Improved expression of recombinant human factor IX by co-expression of GGCX, VKOR and furin
    Protein J33, 174-183. PubMed  Europe PubMed DOI  E
  94. Mancuso,M.E.
    GlycoPEGylated factor IX: a new step forward
    Blood124, 3836-3837. PubMed  Europe PubMed DOI  U
  95. McCue,J., Osborne,D., Dumont,J., Peters,R., Mei,B., Pierce,G.F., Kobayashi,K. and Euwart,D.
    Validation of the manufacturing process used to produce long-acting recombinant factor IX Fc fusion protein
    Haemophilia20, e327-e335. PubMed  Europe PubMed DOI  U
  96. Simhadri,V.L., Hamasaki-Katagiri,N., Tseng,S.C., Bentley,A.A., Zichel,R., Hershko,A.Y., Komar,A.A. and Kimchi-Sarfaty,C.
    Factor IX oligomerization underlies reduced activity upon disruption of physiological conditions
    Haemophilia20, e157-e163. PubMed  Europe PubMed DOI
  97. Venkateswarlu,D.
    Structural insights into the interaction of blood coagulation co-factor VIIIa with factor IXa: a computational protein-protein docking and molecular dynamics refinement study
    Biochem Biophys Res Commun452, 408-414. PubMed  Europe PubMed DOI
  98. Windyga,J., Lissitchkov,T., Stasyshyn,O., Mamonov,V., Rusen,L., Lamas,J.L., Oh,M.S., Chapman,M., Fritsch,S., Pavlova,B.G., Wong,W.Y. and Abbuehl,B.E.
    Pharmacokinetics, efficacy and safety of BAX326, a novel recombinant factor IX: a prospective, controlled, multicentre phase I/III study in previously treated patients with severe (FIX level <1%) or moderately severe (FIX level <=2%) haemophilia B
    Haemophilia20, 15-24. PubMed  Europe PubMed DOI  U
  99. Windyga,J., Solano Trujillo,M.H. and Hafeman,A.E.
    BAX326 (RIXUBIS): a novel recombinant factor IX for the control and prevention of bleeding episodes in adults and children with hemophilia B
    Ther Adv Hematol5, 168-180. PubMed  Europe PubMed DOI
    100. 2013
  100. Bjorkman,S.
    Population pharmacokinetics of recombinant factor IX: implications for dose tailoring
    Haemophilia19, 753-757. PubMed  Europe PubMed DOI  U
  101. Branchini,A., Campioni,M., Mazzucconi,M.G., Biondo,F., Mari,R., Bicocchi,M.P., Bernardi,F. and Pinotti,M.
    Replacement of the Y450 (c234) phenyl ring in the carboxyl-terminal region of coagulation factor IX causes pleiotropic effects on secretion and enzyme activity
    FEBS Lett587, 3249-3253. PubMed  Europe PubMed DOI
  102. Brooks,A.R., Sim,D., Gritzan,U., Patel,C., Blasko,E., Feldman,R.I., Tang,L., Ho,E., Zhao,X.Y., Apeler,H. and Murphy,J.E.
    Glycoengineered factor IX variants with improved pharmacokinetics and subcutaneous efficacy
    J Thromb Haemost11, 1699-1706. PubMed  Europe PubMed DOI  U
  103. Franchini,M., Frattini,F., Crestani,S., Sissa,C. and Bonfanti,C.
    Treatment of hemophilia B: focus on recombinant factor IX
    Biologics7, 33-38. PubMed  Europe PubMed DOI  U
  104. Geng,Y., Verhamme,I.M., Sun,M.F., Bajaj,S.P., Emsley,J. and Gailani,D.
    Analysis of the factor XI variant Arg184Gly suggests a structural basis for factor IX binding to factor XIa
    J Thromb Haemost11, 1374-1384. PubMed  Europe PubMed DOI  M
  105. Lissitchkov,T., Matysiak,M., Zavilska,K., Laguna,P., Gercheva,L., Antonov,A., Moret,A., Caunedo,P., Aznar,J.A., Woodward,M.K. and Paez,A.
    Head-to-head comparison of the pharmacokinetic profiles of a high-purity factor IX concentrate (AlphaNine(R) ) and a recombinant factor IX (BeneFIX(R) ) in patients with severe haemophilia B
    Haemophilia19, 674-678. PubMed  Europe PubMed DOI  U
  106. Matafonov,A., Cheng,Q., Geng,Y., Verhamme,I.M., Umunakwe,O., Tucker,E.I., Sun,M.F., Serebrov,V., Gruber,A. and Gailani,D.
    Evidence for factorIX-independent roles for factorXIa in blood coagulation
    J Thromb Haemost11, 2118-2127. PubMed  Europe PubMed DOI  K
  107. Monzani,P.S., Sangalli,J.R., de Bem,T.H., Bressan,F.F., Fantinato-Neto,P., Pimentel,J.R., Birgel-Junior,E.H., Fontes,A.M., Covas,D.T. and Meirelles,F.V.
    Breeding of transgenic cattle for human coagulation factor IX by a combination of lentiviral system and cloning
    Genet Mol Res12, 3675-3688. PubMed  Europe PubMed DOI  U
  108. Rallapalli,P.M., Kemball-Cook,G., Tuddenham,E.G., Gomez,K. and Perkins,S.J.
    An interactive mutation database for human coagulation factor IX provides novel insights into the phenotypes and genetics of hemophilia B
    J Thromb Haemost11, 1329-1340. PubMed  Europe PubMed DOI  M
  109. Ribeiro,D.A., Passos,D.F., Ferraz,H.C. and Castilho,L.R.
    Anion-exchange purification of recombinant factor IX from cell culture supernatant using different chromatography supports
    J Chromatogr B Analyt Technol Biomed Life Sci938, 111-118. PubMed  Europe PubMed DOI  U
  110. Yang,L. and Rezaie,A.R.
    Residues of the 39-loop restrict the plasma inhibitor specificity of factor IXa
    J Biol Chem288, 12692-12698. PubMed  Europe PubMed DOI
    111. 2012
  111. Buchlis,G., Podsakoff,G.M., Radu,A., Hawk,S.M., Flake,A.W., Mingozzi,F. and High,K.A.
    Factor IX expression in skeletal muscle of a severe hemophilia B patient 10 years after AAV-mediated gene transfer
    Blood119, 3038-3041. PubMed  Europe PubMed DOI  U
  112. Marcinkiewicz,M.M., Sinha,D. and Walsh,P.N.
    Productive recognition of factor IX by factor XIa exosites requires disulfide linkage between heavy and light chains of factor XIa
    J Biol Chem287, 6187-6195. PubMed  Europe PubMed DOI
  113. Milanov,P., Ivanciu,L., Abriss,D., Quade-Lyssy,P., Miesbach,W., Alesci,S., Tonn,T., Grez,M., Seifried,E. and Schuttrumpf,J.
    Engineered factor IX variants bypass FVIII and correct hemophilia A phenotype in mice
    Blood119, 602-611. PubMed  Europe PubMed DOI  U
  114. Monahan,P.E., Velander,W.H. and Bajaj,S.P.
    Coagulation factor IXa
    [ISSN:978-0-12-407742-3]3, 2898-2905. DOI
  115. Perez-Garrido,R., Alonso,N., Jimenez-Yuste,V., Haya,S., Zuniga,P., Baques,A., Candela,M., Davoli,M. and Rescia,V.
    Efficacy of factor IX Grifols((R)) in surgery: experience of an international multicentre retrospective study
    Haemophilia18, e372-e373. PubMed  Europe PubMed DOI  U
  116. Sayyar,B., Dodd,M., Wen,J., Ma,S., Marquez-Curtis,L., Janowska-Wieczorek,A. and Hortelano,G.
    Encapsulation of factor IX-engineered mesenchymal stem cells in fibrinogen-alginate microcapsules enhances their viability and transgene secretion
    J Tissue Eng3, 2041731412462018-2041731412462018. PubMed  Europe PubMed DOI  U
  117. Serban,M., Skotnicki,A.B., Colovic,M., Jinca,C., Klukowska,A., Laguna,P. and Wolf,D.M.
    Clinical efficacy, safety and pharmacokinetic properties of the plasma-derived factor IX concentrate Haemonine in previously treated patients with severe haemophilia B
    Haemophilia18, 175-181. PubMed  Europe PubMed DOI  U
  118. Sun,Y.L., Chang,Y.S., Lin,Y.S. and Yen,C.H.
    Pilot production of recombinant human clotting factor IX from transgenic sow milk
    J Chromatogr B Analyt Technol Biomed Life Sci898, 78-89. PubMed  Europe PubMed DOI  E
  119. Vatandoost,J., Zomorodipour,A., Sadeghizadeh,M., Aliyari,R., Bos,M.H. and Ataei,F.
    Expression of biologically active human clotting factor IX in Drosophila S2 cells: gamma-carboxylation of a human vitamin K-dependent protein by the insect enzyme
    Biotechnol Prog28, 45-51. PubMed  Europe PubMed DOI  E
    120. 2011
  120. Chang,L.C., Yang,C.Y., Chua,A.C., Lin,Y.J. and Lai,S.M.
    Sustained release of transgenic human factor IX: preparation, characterization, and in vivo efficacy
    Mol Pharm8, 1767-1774. PubMed  Europe PubMed DOI  U
  121. Cunha,N.B., Murad,A.M., Ramos,G.L., Maranhao,A.Q., Brigido,M.M., Araujo,A.C., Lacorte,C., Aragao,F.J., Covas,D.T., Fontes,A.M., Souza,G.H., Vianna,G.R. and Rech,E.L.
    Accumulation of functional recombinant human coagulation factor IX in transgenic soybean seeds
    Transgenic Res20, 841-855. PubMed  Europe PubMed DOI  E
  122. de Castilho Fernandes,A., Fontes,A., Gonsales,N., Swiech,K., Picanco-Castro,V., Faca,S. and Covas,D.
    Stable and high-level production of recombinant factor IX in human hepatic cell line
    Biotechnol Appl Biochem58, 243-249. PubMed  Europe PubMed DOI  E  U
  123. Kao,C.Y., Lin,C.N., Yang,Y.L., Hamaguchi,N., Yang,S.J., Shen,M.C., Kao,J.T. and Lin,S.W.
    Characterisation of factor IX with a glycine-to-valine missense mutation at residue 190 in a patient with severe haemophilia B
    Thromb Haemost105, 616-626. PubMed  Europe PubMed DOI  M
  124. Keravala,A., Chavez,C.L., Hu,G., Woodard,L.E., Monahan,P.E. and Calos,M.P.
    Long-term phenotypic correction in factor IX knockout mice by using phiC31 integrase-mediated gene therapy
    Gene Ther18, 842-848. PubMed  Europe PubMed DOI  U
  125. Lissitchkov,T., Matysiak,M., Zavilska,K., Laguna,P., Gercheva,L., Antonov,A., Cabrera,N., Aznar,J.A., Woodward,M.K. and Paez,A.
    A clinical study assessing the pharmacokinetics, efficacy and safety of AlphaNine((R)) , a high-purity factor IX concentrate, in patients with severe haemophilia B
    Haemophilia17, 590-596. PubMed  Europe PubMed DOI  U
  126. Ostergaard,H., Bjelke,J.R., Hansen,L., Petersen,L.C., Pedersen,A.A., Elm,T., Moller,F., Hermit,M.B., Holm,P.K., Krogh,T.N., Petersen,J.M., Ezban,M., Sorensen,B.B., Andersen,M.D., Agerso,H., Ahmadian,H., Balling,K.W., Christiansen,M.L., Knobe,K., Nichols,T.C., Bjorn,S.E. and Tranholm,M.
    Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptide
    Blood118, 2333-2341. PubMed  Europe PubMed DOI  U
  127. Vaccarino,A., Bazzan,M., Giachino,O., Colagrande,P., Ferraresi,P., Stella,S., Roccatello,D. and Bernardi,F.
    Factor IX propeptide mutation and life threatening bleeding
    Thromb Res128, 503-504. PubMed  Europe PubMed DOI
  128. Wootla,B., Christophe,O.D., Mahendra,A., Dimitrov,J.D., Repesse,Y., Ollivier,V., Friboulet,A., Borel-Derlon,A., Levesque,H., Borg,J.Y., Andre,S., Bayry,J., Calvez,T., Kaveri,S.V. and Lacroix-Desmazes,S.
    Proteolytic antibodies activate factor IX in patients with acquired hemophilia
    Blood117, 2257-2264. PubMed  Europe PubMed DOI
    129. 2010
  129. Eikelboom,J.W., Zelenkofske,S.L. and Rusconi,C.P.
    Coagulation factor IXa as a target for treatment and prophylaxis of venous thromboembolism
    Arterioscler Thromb Vasc Biol30, 382-387. PubMed  Europe PubMed DOI  T  I
  130. Ishiwata,A., Mimuro,J., Mizukami,H., Kashiwakura,Y., Yasumoto,A., Sakata,A., Ohmori,T., Madoiwa,S., Ono,F., Shima,M., Yoshioka,A., Ozawa,K. and Sakata,Y.
    Mutant macaque factor IX T262A: a tool for hemophilia B gene therapy studies in macaques
    Thromb Res125, 533-537. PubMed  Europe PubMed DOI  M  U
  131. Johnson,D.J., Langdown,J. and Huntington,J.A.
    Molecular basis of factor IXa recognition by heparin-activated antithrombin revealed by a 1.7-A structure of the ternary complex
    Proc Natl Acad Sci U S A107, 645-650. PubMed  Europe PubMed DOI  S
  132. Lin,C.N., Kao,C.Y., Miao,C.H., Hamaguchi,N., Wu,H.L., Shi,G.Y., Liu,Y.L., High,K.A. and Lin,S.W.
    Generation of a novel factor IX with augmented clotting activities in vitro and in vivo
    J Thromb Haemost8, 1773-1783. PubMed  Europe PubMed DOI  E  U
  133. Lissitchkov,T., Matysiak,M., Zawilska,K., Gercheva,L., Antonov,A., Montanes,M. and Paez,A.
    An open clinical study assessing the efficacy and safety of factor IX Grifols, a high-purity factor IX concentrate, in patients with severe haemophilia B
    Haemophilia16, 240-246. PubMed  Europe PubMed DOI  U
  134. Mazetto Bde,M., Orsi,F.L., Siqueira,L.H., de Mello,T.B., de Paula,E.V. and Annichino-Bizzacchi,J.M.
    Prevalence of factor IX-R338L (factor IX Padua) in a cohort of patients with venous thromboembolism and mild elevation of factor IX levels
    Thromb Res126, e165-e165. PubMed  Europe PubMed DOI  M
  135. Mizurini,D.M., Francischetti,I.M., Andersen,J.F. and Monteiro,R.Q.
    Nitrophorin 2, a factor IX(a)-directed anticoagulant, inhibits arterial thrombosis without impairing haemostasis
    Thromb Haemost104, 1116-1123. PubMed  Europe PubMed DOI
  136. Monahan,P.E. and Di Paola,J.
    Recombinant factor IX for clinical and research use
    Semin Thromb Hemost36, 498-509. PubMed  Europe PubMed DOI  E  V
  137. Peters,R.T., Low,S.C., Kamphaus,G.D., Dumont,J.A., Amari,J.V., Lu,Q., Zarbis-Papastoitsis,G., Reidy,T.J., Merricks,E.P., Nichols,T.C. and Bitonti,A.J.
    Prolonged activity of factor IX as a monomeric Fc fusion protein
    Blood115, 2057-2064. PubMed  Europe PubMed DOI  U
  138. Sam,M.R., Zomorodipour,A., Shokrgozar,M.A., Ataei,F., Haddad-Mashadrizeh,A. and Amanzadeh,A.
    Enhancement of the human factor IX expression, mediated by an intron derived fragment from the rat aldolase B gene in cultured hepatoma cells
    Biotechnol Lett32, 1385-1392. PubMed  Europe PubMed DOI
  139. Sexton,A., Furmedge,J., Barnes,C., Cheetham,G., Wallace,J. and Savarirayan,R.
    Clinical significance of two mutations in the factor IX gene in a family with haemophilia B
    Haemophilia16, 374-376. PubMed  Europe PubMed DOI  M
  140. Verma,D., Moghimi,B., Loduca,P.A., Singh,H.D., Hoffman,B.E., Herzog,R.W. and Daniell,H.
    Oral delivery of bioencapsulated coagulation factor IX prevents inhibitor formation and fatal anaphylaxis in hemophilia B mice
    Proc Natl Acad Sci U S A107, 7101-7106. PubMed  Europe PubMed DOI  U
  141. Wang,S., Beck,R., Blench,T., Burd,A., Buxton,S., Malic,M., Ayele,T., Shaikh,S., Chahwala,S., Chander,C., Holland,R., Merette,S., Zhao,L., Blackney,M. and Watts,A.
    Studies of benzothiophene template as potent factor IXa (FIXa) inhibitors in thrombosis
    J Med Chem53, 1465-1472. PubMed  Europe PubMed DOI  I
  142. Yang,L., Manithody,C., Qureshi,S.H. and Rezaie,A.R.
    Role of the residues of the 39-loop in determining the substrate and inhibitor specificity of factor IXa
    J Biol Chem285, 28488-28495. PubMed  Europe PubMed DOI
    143. 2009
  143. Ghosh,K., Quadros,L. and Shetty,S.
    Spectrum of factor IX gene mutations causing haemophilia B from India
    Blood Coagul Fibrinolysis20, 333-336. PubMed  Europe PubMed DOI  M
  144. Gui,T., Reheman,A., Ni,H., Gross,P.L., Yin,F., Monroe,D., Monahan,P.E. and Stafford,D.W.
    Abnormal hemostasis in a knock-in mouse carrying a variant of factor IX with impaired binding to collagen type IV
    J Thromb Haemost7, 1843-1851. PubMed  Europe PubMed DOI
  145. Hartmann,R., Dockal,M., Kammlander,W., Panholzer,E., Nicolaes,G.A., Fiedler,C., Rosing,J. and Scheiflinger,F.
    Factor IX mutants with enhanced catalytic activity
    J Thromb Haemost7, 1656-1662. PubMed  Europe PubMed DOI  E
  146. Simioni,P., Tormene,D., Tognin,G., Gavasso,S., Bulato,C., Iacobelli,N.P., Finn,J.D., Spiezia,L., Radu,C. and Arruda,V.R.
    X-linked thrombophilia with a mutant factor IX (factor IX Padua)
    N Engl J Med361, 1671-1675. PubMed  Europe PubMed DOI  M
  147. Zogg,T. and Brandstetter,H.
    Structural basis of the cofactor- and substrate-assisted activation of human coagulation factor IXa
    Structure17, 1669-1678. PubMed  Europe PubMed DOI  S
  148. Zogg,T. and Brandstetter,H.
    Activation mechanisms of coagulation factor IX
    Biol Chem390, 391-400. PubMed  Europe PubMed DOI
    149. 2008
  149. Chavali,S., Sharma,A., Tabassum,R. and Bharadwaj,D.
    Sequence and structural properties of identical mutations with varying phenotypes in human coagulation factor IX
    Proteins73, 63-71. PubMed  Europe PubMed DOI  M
  150. Ding,Y., Wang,J., Tan,W., Chen,Y., Lu,X., Lu,Y., Li,S., Li,H., Wang,L. and Cheng,J.
    Cloning, sequencing, and analysis of the full-length CDNA of rhesus monkey factor IX
    Transplant Proc40, 2769-2772. PubMed  Europe PubMed DOI
  151. Gray,E., Pickering,W., Hockley,J., Rigsby,P., Weinstein,M., Terao,E. and Buchheit,K.H.
    Collaborative study for the establishment of replacement batches for human coagulation factor IX concentrate reference standards
    Pharmeuropa Bio2008, 19-30. PubMed  Europe PubMed  A
    152. 2007
  152. Cohn,E.F., Zhuo,J., Kelly,M.E. and Chao,H.J.
    Efficient induction of immune tolerance to coagulation factor IX following direct intramuscular gene transfer
    J Thromb Haemost5, 1227-1236. PubMed  Europe PubMed DOI
  153. Zhang,H., Zhao,L., Chen,Y., Cui,L., Ren,W. and Tang,K.
    Expression of human coagulation factor IX in transgenic tomato (Lycopersicon esculentum)
    Biotechnol Appl Biochem48, 101-107. PubMed  Europe PubMed DOI  E
    154. 2006
  154. [YEAR:5-9-2006]Fribourg,C., Meijer,A.B. and Mertens,K.
    The interface between the EGF2 domain and the protease domain in blood coagulation factor IX contributes to factor VIII binding and factor X activation
    Biochemistry45, 10777-10785. PubMed  Europe PubMed DOI
  155. [YEAR:8-8-2006]Rezaie,A.R., Sun,M.F. and Gailani,D.
    Contributions of basic amino acids in the autolysis loop of factor XIa to serpin specificity
    Biochemistry45, 9427-9433. PubMed  Europe PubMed DOI
  156. Yan,J.B., Wang,S., Huang,W.Y., Xiao,Y.P., Ren,Z.R., Huang,S.Z. and Zeng,Y.T.
    Transgenic mice can express mutant human coagulation factor IX with higher level of clotting activity
    Biochem Genet44, 349-360. PubMed  Europe PubMed DOI  E
  157. [YEAR:2-6-2006]Yang,L., Gopalakrishna,K., Manithody,C. and Rezaie,A.R.
    Expression, purification and characterization of factor IX derivatives using a novel vector system
    Protein Expr Purif50, 196-202. PubMed  Europe PubMed DOI
    158. 2005
  158. Begbie,M.E., Mamdani,A., Gataiance,S., Eltringham-Smith,L.J., Bhakta,V., Hortelano,G. and Sheffield,W.P.
    An important role for the activation peptide domain in controlling factor IX levels in the blood of haemophilia B mice
    Thromb Haemost94, 1138-1147. PubMed  Europe PubMed DOI
  159. [YEAR:10-8-2005]Heeb,M.J., Cabral,K.M. and Ruan,L.
    Down-regulation of factor IXa in the factor Xase complex by protein Z-dependent protease inhibitor
    J Biol Chem280, 33819-33825. PubMed  Europe PubMed DOI
  160. [YEAR:21-9-2005]Shapiro,A.D., Di Paola,J., Cohen,A., Pasi,K.J., Heisel,M.A., Blanchette,V.S., Abshire,T.C., Hoots,W.K., Lusher,J.M., Negrier,C., Rothschild,C. and Roth,D.A.
    The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia B
    Blood105, 518-525. PubMed  Europe PubMed DOI
    161. 2004
  161. [YEAR:1-11-2004]Batt,D.G., Qiao,J.X., Modi,D.P., Houghton,G.C., Pierson,D.A., Rossi,K.A., Luettgen,J.M., Knabb,R.M., Jadhav,P.K. and Wexler,R.R.
    5-Amidinoindoles as dual inhibitors of coagulation factors IXa and Xa
    Bioorg Med Chem Lett14, 5269-5273. PubMed  Europe PubMed DOI  I
  162. [YEAR:20-7-2004]Kerschbaumer,R.J., Riedrich,K., Kral,M., Varadi,K., Dorner,F., Rosing,J. and Scheiflinger,F.
    An antibody specific for coagulation factor IX enhances the activity of the intrinsic factor X-activating complex
    J Biol Chem279, 40445-40450. PubMed  Europe PubMed DOI
  163. [YEAR:16-3-2004]Neuenschwander,P.F.
    Exosite occupation by heparin enhances the reactivity of blood coagulation factor IXa
    Biochemistry43, 2978-2986. PubMed  Europe PubMed DOI
  164. Schmidt,A.E. and Bajaj,S.P.
    Coagulation factor IXa
    [ISSN:0-12-079610-4]2, 1655-1659.  V
  165. Smallheer,J.M., Alexander,R.S., Wang,J., Wang,S., Nakajima,S., Rossi,K.A., Smallwood,A., Barbera,F., Burdick,D., Luettgen,J.M., Knabb,R.M., Wexler,R.R. and Jadhav,P.K.
    SAR and factor IXa crystal structure of a dual inhibitor of factors IXa and Xa
    Bioorg Med Chem Lett14, 5263-5267. PubMed  Europe PubMed DOI  S  I
    166. 2003
  166. [YEAR:1-3-2003]Ameri,A., Kurachi,S., Sueishi,K., Kuwahara,M. and Kurachi,K.
    Myocardial fibrosis in mice with overexpression of human blood coagulation factor IX
    Blood101, 1871-1873. PubMed  Europe PubMed DOI
  167. [YEAR:25-6-2003]Josic,D., Hoffer,L. and Buchacher,A.
    Preparation of vitamin K-dependent proteins, such as clotting factors II, VII, IX and X and clotting inhibitor protein C
    J Chromatogr B Analyt Technol Biomed Life Sci790, 183-197. PubMed  Europe PubMed DOI
  168. Lee,W.H., Zhuang,Q.Y. and Zhang,Y.
    Cloning and characterization of a blood coagulation factor IX-binding protein from the venom of Trimeresurus stejnegeri
    Toxicon41, 765-772. PubMed  Europe PubMed DOI
  169. [YEAR:14-3-2003]Rohlena,J., Kolkman,J.A., Boertjes,R.C., Mertens,K. and Lenting,P.J.
    Residues Phe342-Asn346 of activated coagulation factor IX contribute to the interaction with low density lipoprotein receptor-related protein
    J Biol Chem278, 9394-9401. PubMed  Europe PubMed DOI
  170. Schmidt,A.E. and Bajaj,S.P.
    Structure-function relationships in factor IX and factor IXa
    Trends Cardiovasc Med13, 39-45. PubMed  Europe PubMed DOI
    171. 2002
  171. Bowen,D.J.
    Haemophilia A and haemophilia B: molecular insights
    Mol Pathol55, 127-144. PubMed  Europe PubMed  M  V
  172. [YEAR:6-12-2002]Peek,M., Moran,P., Mendoza,N., Wickramasinghe,D. and Kirchhofer,D.
    Unusual proteolytic activation of pro-hepatocyte growth factor by plasma kallikrein and coagulation factor XIa
    J Biol Chem277, 47804-47809. PubMed  Europe PubMed DOI
  173. [YEAR:20-9-2002]Persson,K.E., Villoutreix,B.O., Thamlitz,A.M., Knobe,K.E. and Stenflo,J.
    The N-terminal epidermal growth factor-like domain of coagulation factor IX. Probing its functions in the activation of factor IX and factor X with a monoclonal antibody
    J Biol Chem277, 35616-35624. PubMed  Europe PubMed DOI
  174. Persson,K.E.M.
    Role of the N-terminal EGF module of coagulation factor IX in activation of factors IX and X
    Scand J Clin Lab Invest62, 13-18.
  175. Rodriguez,M.H., Enjolras,N., Plantier,J.L., Rea,M., Leboeuf,M., Uzan,G., Bordet,J.C. and Negrier,C.
    Expression of coagulation factor IX in a haematopoietic cell line
    Thromb Haemost87, 366-373. PubMed  Europe PubMed
  176. Toomey,J.R., Valocik,R.E., Koster,P.F., Gabriel,M.A., McVey,M., Hart,T.K., Ohlstein,E.H., Parsons,A.A. and Barone,F.C.
    Inhibition of factor IX(a) is protective in a rat model of thromboembolic stroke
    Stroke33, 578-585. PubMed  Europe PubMed DOI
  177. [YEAR:22-2-2002]Wilkinson,F.H., London,F.S. and Walsh,P.N.
    Residues 88-109 of factor IXa are important for assembly of the factor X activating complex
    J Biol Chem277, 5725-5733. PubMed  Europe PubMed DOI
  178. [YEAR:22-2-2002]Wilkinson,F.H., Ahmad,S.S. and Walsh,P.N.
    The factor IXa second epidermal growth factor (EGF2) domain mediates platelet binding and assembly of the factor X activating complex
    J Biol Chem277, 5734-5741. PubMed  Europe PubMed DOI
  179. [YEAR:1-2-2002]Zhong,D., Bajaj,M.S., Schmidt,A.E. and Bajaj,S.P.
    The N-terminal epidermal growth factor-like domain in factor IX and factor X represents an important recognition motif for binding to tissue factor
    J Biol Chem277, 3622-3631. PubMed  Europe PubMed DOI
    180. 2001
  180. Bestmann,L., Zuger,M., Oldenburg,J., Buhler,D. and Maly,F.E.
    Coagulation factor IX propeptide mutations causing coumarin hypersensitivity: Identification of female alanine-10 valine heterozygotes
    Thromb Haemost85, 567-568. PubMed  Europe PubMed
  181. [YEAR:18-9-2001]Hsu,Y.C., Hamaguchi,N., Chang,Y.J. and Lin,S.W.
    The distinct roles that Gln-192 and Glu-217 of factor IX play in selectivity for macromolecular substrates and inhibitors
    Biochemistry40, 11261-11269. PubMed  Europe PubMed DOI
  182. [YEAR:15-1-2001]Imamura,T., Tanase,S., Hamamoto,T., Potempa,J. and Travis,J.
    Activation of blood coagulation factor IX by gingipains R, arginine-specific cysteine proteinases from Porphyromonas gingivalis
    Biochem J353, 325-331. PubMed  Europe PubMed DOI
  183. Melton,L.G., Li,T., Stafford,D.W. and Gabriel,D.A.
    Location of the platelet binding site in zymogen coagulation factor IX
    Blood Coagul Fibrinolysis12, 237-243. PubMed  Europe PubMed DOI
  184. Perera,L., Darden,T.A. and Pedersen,L.G.
    Modeling human zymogen factor IX
    Thromb Haemost85, 596-603. PubMed  Europe PubMed  S
  185. [YEAR:15-12-2001]Roth,D.A., Kessler,C.M., Pasi,K.J., Rup,B., Courter,S.G. and Tubridy,K.L.
    Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates
    Blood98, 3600-3606. PubMed  Europe PubMed DOI
    186. 2000
  186. [YEAR:3-10-2000]Blostein,M.D., Rigby,A.C., Furie,B.C., Furie,B. and Gilbert,G.E.
    Amphipathic helices support function of blood coagulation factor IXa
    Biochemistry39, 12000-12006. PubMed  Europe PubMed DOI
  187. [YEAR:7-1-2000]Celie,P.H., Lenting,P.J. and Mertens,K.
    Hydrophobic contact between the two epidermal growth factor-like domains of blood coagulation factor IX contributes to enzymatic activity
    J Biol Chem275, 229-234. PubMed  Europe PubMed DOI
  188. [YEAR:15-4-2000]Hagstrom,J.N., Couto,L.B., Scallan,C., Burton,M., McCleland,M.L., Fields,P.A., Arruda,V.R., Herzog,R.W. and High,K.A.
    Improved muscle-derived expression of human coagulation factor IX from a skeletal actin/CMV hybrid enhancer/promoter
    Blood95, 2536-2542. PubMed  Europe PubMed
  189. [YEAR:15-9-2000]Kolkman,J.A. and Mertens,K.
    Surface-loop residue Lys316 in blood coagulation Factor IX is a major determinant for Factor X but not antithrombin recognition
    Biochem J350, 701-707. PubMed  Europe PubMed DOI
  190. [YEAR:27-6-2000]Kolkman,J.A. and Mertens,K.
    Insertion loop 256-268 in coagulation factor IX restricts enzymatic activity in the absence but not in the presence of factor VIII
    Biochemistry39, 7398-7405. PubMed  Europe PubMed DOI
  191. Kurachi,K. and Kurachi,S.
    Genetic mechanisms of age regulation of blood coagulation: factor IX model
    Arterioscler Thromb Vasc Biol20, 902-906. PubMed  Europe PubMed
  192. Makino,Y., Omichi,K., Kuraya,N., Ogawa,H., Nishimura,H., Iwanaga,S. and Hase,S.
    Structural analysis of N-linked sugar chains of human blood clotting factor IX
    J Biochem128, 175-180. PubMed  Europe PubMed
  193. [YEAR:1-2-2000]Samis,J.A., Ramsey,G.D., Walker,J.B., Nesheim,M.E. and Giles,A.R.
    Proteolytic processing of human coagulation factor IX by plasmin
    Blood95, 943-951. PubMed  Europe PubMed
    194. 1999
  194. [YEAR:15-8-1999]Hopfner,K.P., Lang,A., Karcher,A., Sichler,K., Kopetzki,E., Brandstetter,H., Huber,R., Bode,W. and Engh,R.A.
    Coagulation factor IXa: the relaxed conformation of Tyr99 blocks substrate binding
    Structure7, 989-996. PubMed  Europe PubMed DOI  S
  195. [YEAR:15-4-1999]Kolkman,J.A., Lenting,P.J. and Mertens,K.
    Regions 301-303 and 333-339 in the catalytic domain of blood coagulation factor IX are factor VIII-interactive sites involved in stimulation of enzyme activity
    Biochem J339, 217-221. PubMed  Europe PubMed DOI
  196. [YEAR:8-10-1999]Kolkman,J.A., Christophe,O.D., Lenting,P.J. and Mertens,K.
    Surface loop 199-204 in blood coagulation factor IX is a cofactor-dependent site involved in macromolecular substrate interaction
    J Biol Chem274, 29087-29093. PubMed  Europe PubMed DOI
    197. 1998
  197. [YEAR:15-5-1998]Chang,J., Jin,J., Lollar,P., Bode,W., Brandstetter,H., Hamaguchi,N., Straight,D.L. and Stafford,D.W.
    Changing residue 338 in human factor IX from arginine to alanine causes an increase in catalytic activity
    J Biol Chem273, 12089-12094. PubMed  Europe PubMed DOI
  198. [YEAR:1-7-1998]Kundu,R.K., Sangiorgi,F., Wu,L.Y., Kurachi,K., Anderson,W.F., Maxson,R. and Gordon,E.M.
    Targeted inactivation of the coagulation factor IX gene causes hemophilia B in mice
    Blood92, 168-174. PubMed  Europe PubMed  K
    199. 1997
  199. Bode,W., Brandstetter,H., Mather,T. and Stubbs,M.T.
    Comparative analysis of haemostatic proteinases: structural aspects of thrombin, factor Xa, factor IXa and protein C
    Thromb Haemost78, 501-511. PubMed  Europe PubMed
  200. [YEAR:17-11-1997]Hopfner,K.P., Brandstetter,H., Karcher,A., Kopetzki,E., Huber,R., Engh,R.A. and Bode,W.
    Converting blood coagulation factor IXa into factor Xa: dramatic increase in amidolytic activity identifies important active site determinants
    EMBO J16, 6626-6635. PubMed  Europe PubMed DOI
  201. Lin,H.F., Maeda,N., Smithies,O., Straight,D.L. and Stafford,D.W.
    A coagulation factor IX-deficient mouse model for human hemophilia B
    Blood90, 3962-3966. PubMed  Europe PubMed  K
  202. [YEAR:28-7-1997]Sturzebecher,J., Kopetzki,E., Bode,W. and Hopfner,K.P.
    Dramatic enhancement of the catalytic activity of coagulation factor IXa by alcohols
    FEBS Lett412, 295-300. PubMed  Europe PubMed DOI
    203. 1996
  203. Boccia,L.M., Lillicrap,D., Newcombe,K. and Mueller,C.R.
    Binding of the Ets factor GA-binding protein to an upstream site in the factor IX promoter is a critical event in transactivation
    Mol Cell Biol16, 1929-1935. PubMed  Europe PubMed
  204. [YEAR:5-7-1996]Freedman,S.J., Blostein,M.D., Baleja,J.D., Jacobs,M., Furie,B.C. and Furie,B.
    Identification of the phospholipid binding site in the vitamin K-dependent blood coagulation protein factor IX
    J Biol Chem271, 16227-16236. PubMed  Europe PubMed DOI
  205. [YEAR:1-1-1996]Giannelli,F., Green,P.M., Sommer,S.S., Poon,M.C., Ludwig,M., Schwaab,R., Reitsma,P.H., Goossens,M., Yoshioka,A. and Brownlee,G.G.
    Haemophilia B (sixth edition): a database of point mutations and short additions and deletions
    Nucleic Acids Res24, 103-118. PubMed  Europe PubMed DOI
  206. Giannelli,F. and Green,P.M.
    The molecular basis of haemophilia A and B
    Baillieres Clin Haematol9, 211-228. PubMed  Europe PubMed DOI
  207. Sugahara,Y., Catalfamo,J., Brooks,M., Hitomi,E., Bajaj,S.P. and Kurachi,K.
    Isolation and characterization of canine factor IX
    Thromb Haemost75, 450-455. PubMed  Europe PubMed
    208. 1995
  208. Brandstetter,H., Bauer,M., Huber,R., Lollar,P. and Bode,W.
    X-ray structure of clotting factor IXa: Active site and module structure related to Xase activity and hemophilia B
    Proc Natl Acad Sci U S A92, 9796-9800. PubMed  Europe PubMed DOI  S
  209. [YEAR:26-9-1995]Freedman,S.J., Furie,B.C., Furie,B. and Baleja,J.D.
    Structure of the calcium ion-bound gamma-carboxyglutamic acid-rich domain of factor IX
    Biochemistry34, 12126-12137. PubMed  Europe PubMed DOI
  210. [YEAR:23-6-1995]Lenting,P.J., ter Maat,H., Clijsters,P.P., Donath,M.J., Van Mourik,J.A. and Mertens,K.
    Cleavage at arginine 145 in human blood coagulation factor IX converts the zymogen into a factor VIII binding enzyme
    J Biol Chem270, 14884-14890. PubMed  Europe PubMed DOI  I
    211. 1994
  211. [YEAR:3-5-1994]Agarwala,K.L., Kawabata,S., Takao,T., Murata,H., Shimonishi,Y., Nishimura,H. and Iwanaga,S.
    Activation peptide of human factor IX has oligosaccharides O-glycosidically linked to threonine residues at 159 and 169
    Biochemistry33, 5167-5171. PubMed  Europe PubMed DOI
  212. [YEAR:4-2-1994]Astermark,J., Hogg,P.J. and Stenflo,J.
    The gamma-carboxyglutamic acid and epidermal growth factor-like modules of factor IXa beta. Effects on the serine protease module and factor X activation
    J Biol Chem269, 3682-3689. PubMed  Europe PubMed
  213. Bristol,J.A., Freedman,S.J., Furie,B.C. and Furie,B.
    Profactor IX: the propeptide inhibits binding to membrane surfaces and activation by factor XIa
    Biochemistry33, 14136-14143. PubMed  Europe PubMed DOI
  214. Lin,S.W., Lin,C.N., Hamaguchi,N., Smith,K.J. and Shen,M.C.
    Characterization of a factor IX variant with a glycine207 to glutamic acid mutation
    Blood84, 1866-1873. PubMed  Europe PubMed  M
  215. [YEAR:26-4-1994]Zhong,D., Smith,K.J., Birktoft,J.J. and Bajaj,S.P.
    First epidermal growth factor-like domain of human blood coagulation factor IX is required for its activation by factor VIIa/tissue factor but not by factor XIa
    Proc Natl Acad Sci U S A91, 3574-3578. PubMed  Europe PubMed
    216. 1993
  216. Bajaj,S.P. and Birktoft,J.J.
    Human factor IX and factor IXa
    Methods Enzymol222, 96-128. PubMed  Europe PubMed DOI  V
    217. 1992
  217. [YEAR:5-9-1992]Nishimura,H., Takao,T., Hase,S., Shimonishi,Y. and Iwanaga,S.
    Human factor IX has a tetrasaccharide O-glycosidically linked to serine 61 through the fucose residue
    J Biol Chem267, 17520-17525. PubMed  Europe PubMed
    218. 1991
  218. [YEAR:15-6-1991]Lawson,J.H. and Mann,K.G.
    Cooperative activation of human factor IX by the human extrinsic pathway of blood coagulation
    J Biol Chem266, 11317-11327. PubMed  Europe PubMed
    219. 1990
  219. [YEAR:5-1-1990]Lin,S.W., Smith,K.J., Welsch,D. and Stafford,D.W.
    Expression and characterization of human factor IX and factor IX-factor X chimeras in mouse C127 cells
    J Biol Chem265, 144-150. PubMed  Europe PubMed
  220. Lozier,J.N., Monroe,D.M., Stanfield-Oakley,S., Lin,S.W., Smith,K.J., Roberts,H.R. and High,K.A.
    Factor IX New London: substitution of proline for glutamine at position 50 causes severe hemophilia B
    Blood75, 1097-1104. PubMed  Europe PubMed
  221. Sarkar,G., Koeberl,D.D. and Sommer,S.S.
    Direct sequencing of the activation peptide and the catalytic domain of the factor IX gene in six species
    Genomics6, 133-143. PubMed  Europe PubMed DOI
  222. [YEAR:1-1-1990]Spitzer,S.G., Warn-Cramer,B.J., Kasper,C.K. and Bajaj,S.P.
    Replacement of isoleucine-397 by threonine in the clotting proteinase factor IXa (Los Angeles and Long Beach variants) affects macromolecular catalysis but not L-tosylarginine methyl ester hydrolysis. Lack of correlation between the ox brain prothrombin time and the mutation site in the variant proteins
    Biochem J265, 219-225. PubMed  Europe PubMed
    223. 1989
  223. Ryan,J., Wolitzky,B., Heimer,E., Lambrose,T., Felix,A., Tam,J.P., Huang,L.H., Nawroth,P., Wilner,G. and Kisiel,W.
    Structural determinants of the factor IX molecule mediating interaction with the endothelial cell binding site are distinct from those involved in phospholipid binding
    J Biol Chem264, 20283-20287. PubMed  Europe PubMed
  224. Ware,J., Diuguid,D.L., Liebman,H.A., Rabiet,M.J., Kasper,C.K., Furie,B.C., Furie,B. and Stafford,D.W.
    Factor IX San Dimas. Substitution of glutamine for Arg-4 in the propeptide leads to incomplete gamma-carboxylation and altered phospholipid binding properties
    J Biol Chem264, 11401-11406. PubMed  Europe PubMed
    225. 1987
  225. Lin,S.W., Dunn,J.J., Studier,F.W. and Stafford,D.W.
    Expression of human factor IX and its subfragments in Escherichia coli and generation of antibodies to the subfragments
    Biochemistry26, 5267-5274. PubMed  Europe PubMed  E
    226. 1985
  226. Anson,D.S., Austen,D.E. and Brownlee,G.G.
    Expression of active human clotting factor IX from recombinant DNA clones in mammalian cells
    Nature315, 683-685. PubMed  Europe PubMed  E
  227. Chen,S.H., Yoshitake,S., Chance,P.F., Bray,G.L., Thompson,A.R., Scott,C.R. and Kurachi,K.
    An intragenic deletion of the factor IX gene in a family with hemophilia B
    J Clin Invest76, 2161-2164. PubMed  Europe PubMed DOI  M
  228. Kisiel,W., Smith,K.J. and McMullen,B.A.
    Proteolytic inactivation of blood coagulation factor IX by thrombin
    Blood66, 1302-1308. PubMed  Europe PubMed
    229. 1984
  229. Anson,D.S., Choo,K.H., Rees,D.J., Giannelli,F., Gould,K., Huddleston,J.A. and Brownlee,G.G.
    The gene structure of human anti-haemophilic factor IX
    EMBO J3, 1053-1060. PubMed  Europe PubMed
  230. Cho,K., Tanaka,T., Cook,R.R., Kisiel,W., Fujikawa,K., Kurachi,K. and Powers,J.C.
    Active-site mapping of bovine and human blood coagulation serine proteases using synthetic peptide 4-nitroanilide and thio ester substrates
    Biochemistry23, 644-650. PubMed  Europe PubMed
  231. Fuchs,H.E., Trapp,H.G., Griffith,M.J., Roberts,H.R. and Pizzo,S.V.
    Regulation of factor IXa in vitro in human and mouse plasma and in vivo in the mouse. Role of the endothelium and the plasma proteinase inhibitors
    J Clin Invest73, 1696-1703. PubMed  Europe PubMed DOI
  232. Lollar,P. and Fass,D.N.
    Inhibition of activated porcine factor IX by dansyl-glutamyl-glycyl-arginyl-chloromethylketone
    Arch Biochem Biophys233, 438-446. PubMed  Europe PubMed
    233. 1983
  233. Link,R.P. and Castellino,F.J.
    Kinetic comparison of bovine blood coagulation factors IXa alpha and IXa beta toward bovine factor X
    Biochemistry22, 4033-4041. PubMed  Europe PubMed
    234. 1981
  234. McRae,B.J., Kurachi,K., Heimark,R.L., Fujikawa,K., Davie,E.W. and Powers,J.C.
    Mapping the active sites of bovine thrombin, factor IXa, factor Xa, factor XIa, factor XIIa, plasma kallikrein, and trypsin with amino acid and peptide thioesters: development of new sensitive substrates
    Biochemistry20, 7196-7206. PubMed  Europe PubMed
  235. [YEAR:10-4-1981]van Dieijen,G., Tans,G., Rosing,J. and Hemker,H.C.
    The role of phospholipid and factor VIIIa in the activation of bovine factor X
    J Biol Chem256, 3433-3442. PubMed  Europe PubMed
    236. 1980
  236. Jackson,C.M. and Nemerson,Y.
    Blood coagulation
    Annu Rev Biochem49, 765-811. PubMed  Europe PubMed DOI
    237. 1979
  237. Davie,E.W., Fujikawa,K., Kurachi,K. and Kisiel,W.
    The role of serine proteases in the blood coagulation cascade
    Adv Enzymol Relat Areas Mol Biol48, 277-318. PubMed  Europe PubMed
    238. 1978
  238. Di Scipio,R.G., Kurachi,K. and Davie,E.W.
    Activation of human factor IX (Christmas factor)
    J Clin Invest61, 1528-1538. PubMed  Europe PubMed DOI
  239. [YEAR:25-3-1978]Lindquist,P.A., Fujikawa,K. and Davie,E.W.
    Activation of bovine factor IX (Christmas factor) by factor XIa (activated plasma thromboplastin antecedent) and a protease from Russell's viper venom
    J Biol Chem253, 1902-1909. PubMed  Europe PubMed
    240. 1977
  240. Osterud,B. and Rapaport,S.I.
    Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation
    Proc Natl Acad Sci U S A74, 5260-5264. PubMed  Europe PubMed
    241. 1976
  241. Fujikawa,K. and Davie,E.W.
    Bovine factor IX (Christmas factor)
    Methods Enzymol45, 74-83. PubMed  Europe PubMed DOI  V

feedback
Page created 8-September-2023

EMBL-EBI logo

© 2025 EBI
Terms of use